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Abstract 
In this study we analysed the changes in the properties of rat cerebral cortex Na+/K+-ATPase in streptozotocin i duced diabetes 
(STZ-diabetes). Special attempt was made to determine whether insulin treatment of diabetic animals could restore the altered parameters 
of this enzyme. Na+/K+-ATPase activity was found to be decreased by 15% after 2 weeks, and by 37% after 4 weeks in diabetic rat 
brains with a parallel decrease in maximal capacity of low affinity ouabain binding sites. There was no significant change in the high 
affinity ouabain binding sites. The K d values did not change significantly. Western blot analysis of brain Na+/K---ATPase isoforms 
indicated a 61 +_ 5.8% and 20 +_ 2,8% decrease of the a~ and 0/3 isoforms, respectively in 4 weeks diabetic animals. Change in the 
amount of the a 2 isoform proved to be less characteristic. Both types of/3 subunit isoform showed a significant decrease in four weeks 
diabetic rats. Our data indicate a good correlation in diabetic rats between changes in Na+/K+-ATPase activity, low affinity ouabain 
binding capacity and the level of a~ isoforrn. While insulin treatment of diabetic animals restored the blood glucose level to normal, a 
complete reversal of diabetes induced changes in Na+/K+-ATPase activity, ouabain binding capacity and Na+/K+-ATPase isoform 
composition could not be achieved, 
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1. Introduction 
Na +/K  +-ATPase is a transmembrane enzyme primarily 
responsible for the active transport of sodium and potas- 
sium in mammalian cells [1]. This protein is greatly ex- 
pressed by neurons and consuming 30-60% of brain ATP 
stores it maintains the electrical potential necessary for 
excitability of this tissue [2]. The enzyme exists as a 
heterodimer, there are three isoforms of the catalytic alpha 
(0/) subunit and at least two of the beta (/3) chain [3,4]. 
The 0/ isoforms differ from each other in several biochem- 
ical and physiological characteristics and display a cell and 
tissue specific distribution [4,5]. The a I isoform is widely 
Abbreviations: C, control rats; DAG, diacylglycerol; D2, 2 weeks 
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distributed in all tissues, while a z and 0/3 expression is 
mostly limited to excitable cells [4,6,7]. In brain the 0/3 
isoform is solely expressed by neurons, but both neurons 
and glia cells express the 0/1 or 0/2 isoforlTIS [8,9]. The 
distribution of fl subunit isoforms in different cells is less 
well characterized, fll has a broad distribution, while r2 
is localized mostly to glia [10]. The significance of the 
tissue and cell specific distribution of the subunit isoforms 
is not known, but evidence is slowly accumulating to 
suggest hat 0/ isoforms may be differentially regulated by 
physiological and pathological stimuli I11-13]. Some data 
show that Na+/K+-ATPase isoform ratio changes during 
development in brain and heart, furthermore certain hor- 
mones alter both isoform ratio and isoform abundance 
[ 14-16], It has also been demonstrated that Na +/K  +-pump 
sites were considerably reduced in skeletal muscle and 
adipose tissue in streptozotozin i duced diabetes mellitus 
[17,18], and insulin administration enhanced Na+/K  +- 
ATPase activity [19]. It seems that the 0/2 isoform is 
mostly responsible for insulin action in these tissues 
[20,21]. Recent data show that streptozotocin duced dia- 
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betes causes a decrease of brain Na+/K+-ATPase activity 
[22]. Insulin has been demonstrated to stimulate the synap- 
tosomal Na+/K+-ATPase activity [23]. Mayamil and his 
coworkers reported, that alloxan diabetes induced an initial 
decrease followed by an increase in rat brain Na+/K +- 
ATPase activity which was corrected by insulin adminis- 
tration [24]. The questions remain whether similar changes 
could be detected in brain cortex Na+/K+-ATPase activity 
in streptozotocin i duced diabetes, whether the alteration 
of Na+/K+-ATPase activity results from a quantitative 
decrease of a specific isoform of the enzyme protein or 
from inactivation of the enzyme. The aim of this study was 
to investigate the Na+/K+-ATPase activity and the P~ 
facilitated ouabain binding, as well as the isoenzyme com- 
position of brain cortex derived from normal and STZ-di- 
abetic rats with and without insulin treatment. Some pre- 
liminary results were published elsewhere [25]. 
2. Materials and methods 
2.3. Analytical methods 
Preparation of cerebral cortex microsomal fractions 
1 g of cortex was homogenized in 10 ml of 0.25 M 
sucrose 10 mM Tris, pH 7.4 containing 2 mM PMSF, 1 
/zg aprotinin by a Janke Kungel homogenizer (Germany) 
for 20 s with half maximal speed. The homogenate was 
centrifuged at 2500 × g for 10 min and the pellet was 
discarded, The supernatant was then centrifuged at 100 000 
× g for 60 rain in a Centrikon TFT 70.38 rotor. The pellet 
(crude microsome) was finally suspended in homogenizing 
medium and stored at -80°C [27]. 
Protein content 
Protein content was assayed by the method of Bradford 
using ovalbumin as standard [28]. 
Blood glucose 
Blood glucose was estimated at the same time of day 
using the Boehringer-Mannheim kit.
2.1. Materials 
Crystalline porcine insulin was obtained from NOVA 
(Denmark). Antibodies against rat Na+/K+-ATPase were 
purchased from Upstate Biotechnology (UBI) (Lake Placid, 
NY, USA). Peroxidase conjugated goat anti rabbit antibod- 
ies were from DAKO (Germany), and streptozotocin, 
phenylmethylsulfonyl fluoride (PMSF), bovine serum al- 
bumin (BSA), ovalbumin, aprotinin were obtained from 
Sigma (St. Louis, MO, USA). Immobilon-P Transfer 
Membrane was a Millipore (Bedford, MA, USA) product, 
[3H]ouabain (1.22 TBq/mmol) and ECL Western blotting 
detection reagent were those of Amersham (Amersham, 
UK), blood glucose assay kits were from Boehringer 
(Mannheim, Germany). 
2.2. Animals 
Male Sprague-Dawley rats weighing between 180-210 
were used for the experiments. Streptozotocin (STZ) (60 
mg/kg body weight i.v.) in 100 mM citrate buffer pH 5.5 
was given to a group of randomly selected animals [26]. 
Diabetes was verified 24 h later by estimating hyper- 
glycemia and glucosuria. The first group of diabetic ani- 
mals was killed after 2 weeks (D 2) and another group after 
4 weeks (D 4) of STZ administration. In insulin replace- 
ment studies ultralente insulin was administrated daily to 
the 2 and 4 weeks diabetic rats. Insulin was given in an 
individual dose to normalize blood glucose level during 2 
weeks before the time of the assay (D2R, D4R). Control 
animals (C) were kept under the same condition as diabetic 
rats and used as age-matched control after 2, 4 and 6 
weeks, respectively. The rats were killed by decapitation 
and the brains were immediately removed. The cerebral 
cortex was isolated and rapidly frozen in liquid nitrogen. 
[~ H]Ouabain binding 
[3H]Ouabain binding was performed as described be- 
fore [29] with minor modifications. Crude microsomal 
fractions (100 /zg) were incubated for 2 h at 37°C in l ml 
medium containing 3 mM MgC12, 3 mM imidazole/PO 4,
pH 7.25, [3H]ouabain (1.22 TBq/mmol) and unlabelled 
ouabain in final concentrations of 2 .10-  8_5 • 10- 5 M 
(spec. act. 500-15 000 cpm/pmol) .  Nonspecific 
[3H]ouabain binding was measured in the presence of 1 
mM unlabelled ouabain. The samples were filtered on 
Whatman GFC filters. Filters were washed and counted by 
liquid scintillation. Maximal binding (Bm~ x) expressed in 
pmol per mg of protein, and the dissociation constant (K d) 
expressed in nmol or /xmol per 1, were calculated accord- 
ing to the methods of Scatchard [30] using a computer 
program ENZFITTER (version 1.05 EGA single ligand 
two binding sites model, Elsevier-Biosoft, Cambridge, 
UK). 
Na +/K  +-ATPase activity 
Na+/K+-ATPase activity was assayed according to 
Somogyi [31] with minor modifications. Briefly, the assay 
mixture in a final volume of 1 ml contained microsome 
(50/~g) and a buffer of 50 mM Tris/HCl pH 7.4, 20 mM 
KC1, 100 mM NaC1, 1 mM EGTA, 5 mM MgC12 and 5 
mM ATP. The control tubes contained the same reaction 
mixture and 1 mM ouabain. The reaction was started by 
the addition of ATP and the tubes were incubated at 37°C 
for l0 rain. The reaction was stopped by the addition of 
500 /~1 of 20% TCA, and the amount of inorganic phos- 
phate was determined [31]. The Na+/K+-ATPase activity 
(100%) represents the difference between the activity in 
the presence and absence of 1 mM ouabain. Inhibition 
percentages were calculated by comparing the activities in 
the presence of different concentration of ouabain to the 
/(. Vrr et al./ Biochimica et Biophysica Acre 1237 (1995) 143-150 145 
100% value. The experimental data were fitted using ENZ- 
FITTER (Biosoft, Elsevier, Cambridge, UK). The follow- 
ing model was used: 
V = Z , ,~C/ ( IC~ + C) 
where V is the observed velocity at a given inhibitor 
concentration (C) and Vm~ × is the maximal velocity of 
Na+/K+-ATPase. The best fit curve was calculated using 
non-linear regression [32]. 
The amount of inorganic phosphate determined in the 
presence of 1 mM ouabain represents the Mg2+-ATPase 
activity [31 ]. 
5'-Nucleotidase 
5'-Nucleotidase was determined in the presence of 50 
mM Tris-HCl pH 9.0, 10 mM MgC12, 10 mM AMP, 100 
mM KC1, 100 /.Lg crude microsomal protein. The reaction 
was started by the addition of the microsomal protein and 
the tube was incubated for 20 rain at 37°C. After stopping 
the reaction by addition of 500 /zl 20% TCA [33], the 
amount of inorganic phosphate was determined as above. 
SDS-PAGE 
Crude microsomal proteins (50 ~g) were resolved by 
sodium dodecylsulfate-polyacrylamide gel lectrophoresis 
(SDS-PAGE) according to the method of Laemmli [34]. 
Samples were solubilized in a buffer consisting of 0.125 M 
Tris, pH 6.7, containing 4% SDS, 1 mM EDTA, 15% 
glycerol, 0.1 M dithiotreitol, and 0.01% bromophenol b ue. 
The samples were heated for 15 rain in 98°C and loaded 
on a discontinuous polyacrylamide gel (stacking el 3.4% 
acrylamide pH 6.7, resolving el 7.5% acrylamide pH 8.9). 
The running buffer contained 0.2 M glycine, 2 mM EDTA, 
25 mM Tris and 0.1% SDS. Molecular weight markers 
were the low molecular weigh prestained SDS standard of 
Bio-Rad (Hercules, CA). 
Western blot analysis 
Crude microsomal proteins resolved on SDS-PAGE 
were transferred onto nitrocellulose sheets with a Milliblot 
SDE transfer system (Millipore, Bedford, MA) using a low 
ionic discontinuous buffer system (anode buffer-l: 0.3 M 
Tris and 10% methanol, pH 10.4, anode-2:25 mM Tris 
and 10% methanol, pH 10.4, cathode buffer: 25 mM Tris, 
40 mM glycine, and 20% methanol, pH 9.4). Transfers 
were routinely carried out at 23°C for 15 min at 25 mA 
followed by 45 min at 200 mA. The nitrocellulose was 
fixed for 1 hour in a blot solution containing 5% BSA, 
0.5% Tween 20, 150 mM NaCl, 20 mM Tris pH 7.5 
solution followed by 16 h (4°C) incubation with antibodies 
of the Na*/K+-ATPase subunit isoforms (UBI, USA), 
diluted to 1:500. Blots were washed three times and then 
incubated by peroxidase conjugated goat anti-rabbit sec- 
ondary antibody for 2 h at 23°C. The blots were washed 
three times and developed with the ECL Western blotting 
detection reagent [35]. The film negatives were analyzed 
by laser densitometry. 
2.4. Statistical analysis 
A Student's t-test was used throughout this study to 
compare the differences in various parameters examined. 
The difference between the means was considered to be 
significant if P < 0.05. Data were analyzed by non-linear 
least squares procedures. As indicated the best fit curve 
was calculated using non-linear regression [32]. 
3. Results 
3.1. Body weight and blood glucose 
All animals treated with STZ, developed hyperglycemia 
on the following day (blood glucose level was minimum 
25 raM). The body weight of STZ-diabetic rats was signif- 
icantly lower after the 2 and 4 weeks than the age-matched 
non diabetic ontrols (Table 1). The blood glucose level of 
the STZ-diabetic groups were 3.7-and 4.2-fold higher than 
those of age-matched non diabetic ontrols. Blood glucose 
was decreased close to the control level by insulin admin- 
istration and a relative body weight gain was also observed 
during two weeks of insulin administration. 
Table 1 
Body weight and blood glucose levels in control, STZ-diabetic and insulin-treated STZ-diabetic rats 
Groups C (17) D2 (I3) D4 (16) D2R (14) D4R (14) 
Body weight (g) 
initial 190 4- 24 196 +- 18 218 + 20 187 _+ 19 198 + 20 
2 weeks 211 +24 176_+ 18 196_+ 19 * 167_+ 15 ~ 178+_ 15 ~ * 
4 weeks 227 _+ 24 - 183 _+ 19.8 .... 181 _+ 20 '~ ~ 166 _+ 18 ~' 
6 weeks 236_+ 24 - - - 188_+ 21 * 
Glucose (raM) 7.8 + 1.5 28.7 +_ 3.5 * ~= 32.8 -+ 3.6 ~ • 8.8 -+ 2.6 ;" * 9.8 _+ 2.5 
Experimental diabetes was induced by streptozotocin injection (60 mg/kg body weight i.v.). Diabetic rats were killed either after 2 weeks (D 2 group) or 
after 4 weeks (D 4 group). Insulin treatment was started after 2 or 4 weeks of STZ administration (groups D2R, D4R, respectively) and continued for 2 
weeks as described inMaterials and methods. Data are means +S.E., n = number of experimental animals. Statistically significant (P < 0.05) differences 
between the age-matched controls and either STZ-diabetic or insulin treated STZ-diabetic rats are denoted by *. Statistically significant (P < 0.05) 
differences between STZ -diabetic (D 2 and D 4) and insulin treated STZ diabetic (D2R, D4R) rats are denoted by * *. 
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3.2. Enzyme activities of brain microsomes 
We have summarized the activity of ouabain sensitive 
Na+/K+-ATPase, Mg2+-ATPase and 5'-nucleotidase in
crude microsomal fractions prepared from control, 2 and 4 
weeks diabetic (D 2 and D 4) and diabetic insulin treated 
animals (D2R and D4R) in Table 2. The activity of all the 
three enzymes was the same in the two, four and six weeks 
control groups, therefore C represents all the age-matched 
control groups in the presentation f the results. In the first 
two weeks of diabetes there was a small, but significant 
change ( -  15%) in the activity of brain cortex Na+/K +- 
ATPase. A more pronounced decrease ( -37%)  in 
Na+/K+-ATPase activity was observed in the 4 weeks 
diabetic state (D4). Two weeks insulin treatment restored 
the enzyme activity in all of diabetic animals. 
MgZ+-ATPase activity was significantly higher in dia- 
betic animals (near + 30%) independently of the duration 
of diabetes. Insulin treatment reduced the activity of 
Mg2+-ATPase to the control level in both 2 and 4 week 
diabetic groups. 5'-Nucleotidase activity was found to be 
equal in all groups investigated. These data indicated that 
the decrease in Na÷/K+-ATPase activity was not at- 
tributable to nonspecific damage of the proteins during 
separation of microsomes. 
Testing the ouabain dependence of the Na +/K +-ATPase 
activity of brain microsomes we have found significant 
differences in ouabain sensitivity of Na+/K÷-ATPase pre- 
pared from control, 4 weeks diabetic and 4 weeks diabetic 
insulin treated rats (Fig. 1). The ouabain sensitivity of the 
microsomes derived from 4 week diabetic animals shifted 
to lower ouabain concentration. The ouabain concentration 
producing half maximal inhibition was 8.34 + 0.19/zM in 
the case of the control and 2.84 + 0.15 /xM in 4 weeks 
diabetic animals. This alteration was partly diminished by 
insulin treatment, 4.18 + 0.15 /zM ouabain resulted half 
maximal inhibition in STZ-diabetic insulin treated animals. 
Less pronounced ifferences were detected in ouabain 
sensitivity in 2 weeks diabetic and 2 weeks diabetic insulin 
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Fig. 1. Na+/K+-ATPase inhibition by ouabain in cerebral microsomal 
membranes from control and from four weeks diabetic rats without and 
with insulin treatment. Data are expressed as percent of maximal ouabain 
sensitive Na+/K+-ATPase activity in control (v )  four weeks diabetic 
rats without (O) and with (0 )  insulin treatment, respectively. The data 
are means+S.E, of minimum of three determinations performed in 
duplicates. Computed ICs0 values are 8.34+0.19 p~M in the case of the 
control and 2.845:0.15 /zM in 4 weeks diabetic and 4.185:0.15 /zM in 
insulin treated diabetic animals. Mathematical analysis was performed in 
Materials and methods. P < 0.001 for differences from control; P < 0.01 
for differences from insulin treated diabetic group. 
3.3. [-~H]Ouabain binding capacity 
The basic characteristic of [3 H]ouabain binding to brain 
cortex microsomes from control, diabetic and diabetic 
insulin treated groups were assessed in a series of experi- 
ments. We defined relative [3 H]ouabain affinities over the 
concentration 2. l0 -8 to l0 -5 M to evaluate the binding 
sites and to determine the K d values. In this concentration 
range Scatchard type plot gives two populations of binding 
sites with apparent dissociation constant in the control 
group (gd l  = 62.4 + 5.9 /zmol in the case of low affinity 
binding site and Kd2 = 112.3 _+ 14.8 nmol in the case of 
high affinity binding sites). We did not investigate individ- 
ually the high and very high affinity binding sites. Max±- 
Table 2 
Ouabain sensitive Na+/K+-ATPase, Mg2+-ATPase and 5'-nucleotidase activities in cerebral cortex microsomes from controls, STZ-diabetic and insulin 
treated STZ-diabetic rats 
Experimental group C (n = 17) D 2 (n = 5) D4 (n = 6) D2R (n = 5) D4R (n = 5) 
Na+/K+-ATPase (nmol Pi min- i mg protein- ]) 589.2 + 41 500.8 5:55 * 371.5 5:36 * 561.1 + 47 * * 614.4 _+ 6 * * 
Mg2+-ATPase (nmol Pi min- i mg protein- i) 255.6 _+ 25 319.2 ± 34 * 325.2 ± 29 ~ 236.8 + 31 * ~ 243.3 5:21 * * 
5'-Nucleotidase (nmol Pi rain- ] mg protein - i ) 72.1 _+ 8.1 65.9 _+ 7.2 67.5 + 7.15 69.5 ± 8.2 75.9 ± 5.2 
Cerebral cortex microsomal Na+/K+-ATPase, Mg2+-ATPase and 5'-nucleotidase activities were determined using the methods described in Materials and 
methods. Values are means ± S.E., n = number of experiment. The activity of all of the enzymes investigated was the same in the 2, 4 and 6 weeks control 
groups, therefore C denotes all the age-matched control groups. Statistically significant (P < 0.05) differences between controls and either STZ-diabetic 
(D 2 and D 4) or insulin treated STZ-diabetic rats (D 2 R, D4R) are denoted by *. Statistically significant (P < 0.05) differences between STZ-diabetic (D 2 
and D 4) and insulin treated STZ-diabetic (D2R, D4R) rats are denoted by * *. 
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Table 3 
Maximal ouabain binding capacity and K d values of cerebral cortex microsomes from control, STZ-diabetic and insulin treated STZ-diabetic rats 
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Groups Low affinity sites High affinity sites 
K a (/xmol) B . . . .  (pmol/mg protein) K a (nmol) Bma x (pmol/mg protein) 
C (n = 16) 62.4 _+ 5.9 43.1 _+ 4.3 112.3 _+ 14.8 35 _ 4.3 
D 4 (n = 7) 65.6 + 9.7 23.2 + 3.9 * 117.7 + 17.2 34.6 + 3.6 
D4R (n = 5) 70.2 + 8.3 38.8 _+ 4.2 * '* * "* * * 99.5 + 18.3 43.9 + 4.6 . . . . . .  
Maximal ouabain binding capacity (Bma x) of brain cortex microsomes were determined as described in Materials and methods. Values are means + S.E., 
n = number of experiments. The Bma x and K d values were the same in the 2, 4 and 6 weeks control groups, therefore C denotes all the age-matched 
control groups. Statistically significant (P < 0.05) differences between control and STZ-diabetic (D 4) are denoted by *. Statistically significant (P < 0.05) 
differences between control and insulin treated STZ-diabetic (D4R) rats are denoted by * *. Statistically significant (P < 0.05) differences between 
STZ-diabetic (D 4) and insulin treated STZ-diabetic (DzR) rats are denoted by * * *. 
mal [3H]ouabain binding capacity of the brain tissue was 
reduced in STZ-induced iabetes compared to the control 
and to the diabetic insulin treated animals. Changes in 
ouabain binding capacity proved to be significant in four 
week diabetic animals. The reduction in ouabain binding 
was particularly pronounced at the low affinity ouabain 
binding site and was mostly reversed by insulin treatment, 
although the K a values did not change significantly (Table 
3). No significant changes were detected between the 
control and 2 weeks diabetic as well as 2 weeks diabetic 
insulin treated groups (data are not shown). 
3.4. Na+/K+-ATPase isoforms of brain cortex micro- 
somes 
The ot subunit isoform composition of Na+/K+ATPase 
was altered in STZ-induced diabetes. Fig. 2A shows a 
representative Western blot of subunit isoforms, while the 
B part contains the densitometric analysis of all the data. 
After two weeks of streptozotocin treatment there was a 
significant decrease (23 + 3.1%) in the amount of the C~l 
isoform. At the same time the amount of a z isoform 
increased by 24_  3.1% and the level of ce 3 isoform did 
not change significantly. 
The isoform pattern of the 4 weeks diabetic samples 
differed from the 2 weeks diabetic and also from control. 
The relative amount of aj decreased to a greater extent 
after 4 weeks than in 2 weeks diabetes (61 _+ 5.8 and 
23 + 3.1%, respectively). The amount of ce 2 was the same 
as in the control samples, but 24 ___ 3.1% lower than in D 2 
samples. The amount of oL 3 was 20 q- 2.8% lower than in 
the control ones. 
Two weeks insulin treatment of diabetic animals did not 
restore the original isoform pattern completely (D2R, D4R). 
The relative amount of % isoform in diabetic insulin 
treated animals remained at the same level as in the 
untreated iabetic samples. The amount of a 2 decreased 
during 2 weeks insulin treatment to the same level as in 
the control. The main difference between 2 weeks diabetic 
animals with and without insulin treatment was found in 
the relative amount of the a 3 isoform. In D2R samples the 
quantity of a 3 isoform increased by 39 _+ 3.1% compared 
A. 
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Fig. 2. Relative abundance of Na+/K+-ATPase a subunit isoforms in cerebral cortex of control, STZ-diabetic and STZ-diabetic insulin treated rats. 
Microsomal membranes (50 /xg) of cerebral cortex from control (C), 2 weeks STZ-diabetic without (D 2) and with insulin treatment (D2R), 4 weeks 
STZ-diabetic without (D 4) and with insulin treatment (D4R) were subjected to SDS-PAGE. Relative abundances of ct I , oz 2 and ot 3 were quantitated by 
immunoblotting using isoform specific antiserum and peroxidase conjugated antirabbit IgG as primary and secondary antibodies, respectively. (A) A 
representative photo of an ECL developed Western blot of subunit isoforms. (B) Relative densities of Na+/K+-ATPase o~ subunit isoforms. Closed bars: 
oq, open bars: ot 2, dotted bars: ot 3. Data are means + S.E. of 5 experiments. Statistically significant (P < 0.05) differences between controls and either 
STZ-diabetic or insulin treated STZ-diabetic rats are denoted by. Statistically significant (P < 0.05) differences between STZ-diabetic and insulin treated 
STZ-diabetic rats are denoted by x. 
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Fig. 3. Relative abundance of Na+/K+-ATPase /3 subunit isoforms in cerebral cortex of control, STZ-diabetic and STZ-diabetic nsulin treated rats. 
Microsomal membranes (50 /xg) of cerebral cortex from control (C), 2 weeks STZ-diabetic without (D 2) and with insulin treatment (D2R), 4 weeks 
STZ-diabetic without (D 4) and with insulin treatment (D4R) were subjected to SDS-PAGE. Relative abundance of /31 and /32 were quantitated by
immunoblotting using isoform specific antiserum and peroxidase conjugated antirabbit IgG as primary and secondary antibodies, respectively. (A) A 
representative photo of an ECL developed Western blot of /3 subunit soforms. (B) Relative densities of Na+/K+-ATPase /3 subunit soforms. Closed 
bars: /31, open bars: /32. Data are means ± S.E. of 5 experiments. Statistically significant (P < 0.05) differences between controls and either STZ-diabetic 
or insulin treated STZ-diabetic rats are denoted by. Statistically significant (P < 0.05) differences between STZ-diabetic and insulin treated STZ-diabetic 
rats are denoted by x. 
to the age-matched control, and 46 + 5.1% compared to 
the untreated diabetic group, respectively. The relative 
amount of all the isoforms changed similarly in D4R than 
in D2R rats. The amount of cq increased, but did not 
reached the control level, c% isoform was over the control 
(Fig. 2B). 
A representative experiment and the densitometric anal- 
ysis of Western blots of Na+/K+-ATPase /3 subunit 
isoforms of control, diabetic and diabetic insulin treated 
animals can be seen in Fig. 3A and B, respectively. The 
quantity of both the /31 and /32 isoforms enhanced signifi- 
cantly after two weeks diabetes by 23 -t- 3.1 and 32 __+_ 4.1% 
respectively. On the other hand, the level of both /31 and 
/32 decreased by nearly 20% compared to the control in 4 
weeks diabetic animals. When we compared the relative 
amount of /3 isoforms in D 2 and D 4 diabetic animals, 
more than 40% decrease could be observed in the case of 
both /3 isoforms within a 2 weeks period of diabetic state, 
namely from the second to the fourth week of the disease. 
Insulin treatment did not have any significant effect on 2 
weeks diabetic animals but restored the relative abundance 
of /3 subunits to the control level in the case of 4 weeks 
diabetes. 
4. Discussion 
It is well established that the Na+/K+-ATPase activity 
in the peripheral nervous system is decreased in STZ-in- 
duced diabetes [36,37]. Less experimental data are avail- 
able of diabetic alterations in the central nervous system. 
According to an earlier report brain Na+/K+-ATPase 
activity decreases in diabetes by 5-30% depending on the 
region of the brain examined [22]. Our study shows that 
the Na+/K+-ATPase activity is significantly reduced 
(37%) in brain cortex microsomes in STZ-induced dia- 
betes. 
The reduction of diabetic Na+/K+-ATPase activity 
does not derive from the altered purity of the microsomes 
prepared from the animals of different experimental groups, 
because the 5'-nucleotidase activity is the same in the 
preparations and MgZ+-ATPase activity changes to the 
opposite direction than Na+/K+-ATPase. A decrease in 
Na+/K+-ATPase activity from 589.2 + 41 to 371.5 _+ 36 
nmol P i /mg protein per rain can be observed in 4 weeks 
diabetic animals. If the molecular activity of Na+/K  +- 
ATPase is assumed 7500/min [38] this change corre- 
sponds to the decrease in Na+/K+-pump concentration 
from 78.5 to 49.5 pmol /mg protein. 
As reported earlier, the c~ subunit of Na+/K+-ATPase 
is responsible for ouabain binding, and the different iso- 
forms of c~ subunit show different ouabain binding affini- 
ties [39]. There is only one low affinity ouabain binding 
isoform (cq) and two high affinity ouabain binding iso- 
forms (c~ 2 and c%), the latter two isoforms have very 
similar affinity constants for ouabain [4,6]. According to 
our results in diabetes we have got a reduction in ouabain 
binding capacity of the low affinity binding sites, which 
corresponds to a reduction in the level of the c~ isoform. 
The high affinity binding sites do not change significantly. 
The diabetes induced reduction of low affinity [3H]ouabain 
binding site from 43.1 -t- 4.3 to 23.2 + 3.9 pmol /mg pro- 
tein is in the same range as the change in Na+/K+-pump 
concentrations (78.5 and 49.5 pmol /mg protein in control 
and 4 weeks diabetic groups, respectively). 
In contrast o skeletal muscle [17], in brain cortex the 
number of low affinity binding sites decreases in diabetes. 
The high affinity binding sites do not change significantly, 
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however we have not analyzed separately the high and the 
very high affinity binding sites. Insulin treatment resulted 
in a small enhancement of low affinity sites, while it 
caused a significant increase in high affinity binding sites, 
similarly to the results of Brodsky in brain synaptosomal 
preparation [23]. 
Similar conclusion can be drawn from the changes in 
the ouabain sensitivity of the enzyme after STZ-treatment 
(Fig. 1). The ouabain concentration producing 50% inhibi- 
tion of Na+/K÷-ATPase activity was 8.34 + 0.19 /xM in 
the case of the control and 2.84 + 0.15 /xM in 4 weeks 
diabetic animals. This alteration was partly diminished by 
insulin treatment, he IC50 value enhanced to 4.18 + 0.15 
/xM, but remained significantly different from the control. 
This phenomenon suggests the reduction of the less ouabain 
sensitive isoform of Na+/K÷-ATPase in diabetes. Insulin 
treatment partly restores original ouabain sensitivity of 
Na÷/K+-ATPase in brain cortex. 
The question arises whether the changes in Na÷/K +- 
ATPase activity, ouabain sensitivity, and ouabain binding 
capacity in diabetes are due to alterations of biochemical 
properties of the enzyme or derive from the quantitative 
changes of the isoforms of the transport molecule. Data 
available on peripheral nerve tissue suggest that the reduc- 
tion of Na+/K+-ATPase activity is a consequence of a 
decrease of the enzyme protein [36,37]. 
To evaluate the expression of Na÷/K+-ATPase iso- 
form, antisera specific for %, %, c%, /31 and /32 subunits 
were used to probe Western blots of cerebral cortex micro- 
somes prepared from control, STZ treated diabetic and 
STZ treated insulin injected rats. A significant decrease 
was observed in the level of the diabetic o~ isoform. This 
finding correlates with the enzyme activity and ouabain 
binding data. Change in the levels of diabetic oq isoform 
is in disagreement with the earlier idea, that the c~ 1 iso- 
form functions as a basal Na+/K÷-ATPase and is not 
supposed to be hormonally affected [40]. However, there 
are other data showing that the synthesis and degradation 
rate of c~ 1 isoform are enhanced in the nervous ystem of 
spontaneously diabetic rats [41]. In contrast o other tis- 
sues, where ot 2/3j isoform composition was regulated by 
insulin [17,21], our results show that both ce I and ce 3 as 
well as /31 and /32 isoforms change in diabetic brain and 
are affected by insulin. However, the amount of/3 subunit 
did not change parallel with the Na+/K÷-ATPase activity. 
This finding is in agreement with other data obtained on 
muscle [13]. 
The most important observations of the present study 
are: (1) changes in Na+/K÷-ATPase nzyme activity are 
correlated with the reduction of [3H]ouabain binding ca- 
pacity; (2) the change in enzyme activity and ouabain 
binding correlate with a reduction in the level of c~ I
isoform detected by Western blot analysis; (3) there was 
no correlation between changes in Na÷/K+-ATPase activ- 
ity and the amount of its /3 subunit; (4) there are more 
than one type of a (%, a 3) and /3 (/3r and /3 2) isoforms 
which can be affected in diabetes and by insulin adminis- 
tration. 
The physiological significance of these alterations of 
brain cortex Na÷/K+-ATPase in diabetes remains to be 
clarified [42]. A variety of structural and biochemical 
alterations have been described in the central nervous 
system of diabetic patients and animals [43,44]. Since the 
% isoform localizes to both glia cells and neurons, and a 3 
can be detected only in neurons [8,9], our results suggest 
that the reduction of Na÷/K+-ATPase activity in diabetes 
may participate in changes of both neuron and glia cell 
functions. 
The question whether the observed alteration in experi- 
mental diabetes is derived from the absence of insulin, 
from the relative overflow of glucagon and other hormones 
or from other metabolic disorders is not resolved in this 
study [45,46]. One possibility to explain the changes in 
diabetic Na--/K÷-ATPase function is that through the 
enhanced synthesis of sorbitol, the myo-inositol turnover is 
damaged, resulting in the inactivation of Na+/K÷-ATPase 
[47-49]. Several reports how that in rat brain in streptozo- 
tocin induced diabetes there is a high myo-inositol and 
glucose level [50]. According to other reports there is a 
defect in PMA and DAG responsive Na+/K*-ATPase in 
peripheral nerve of diabetic animals, and this corresponds 
to an altered myo-inositol turnover [47]. 
Another explanation is that insulin exerts a rapid effect 
on gene transcription through upstream insulin response 
elements (IRE) [51]. However, there are also data showing 
a prolonged latency of changes in the synthesis of 
Na+/K+-ATPase catalytic subunit after insulin administra- 
tion [41], and these results suggest hat the regulation of 
Na+/K÷-ATPase activity in diabetes does not directly 
take place through insulin response elements. Besides 
changes in the transcription of Na+/K÷-ATPase we also 
have to consider the possible changes in the translation, 
translocation and degradation of the enzyme in diabetes. 
The investigation of these aspects is in progress in our 
laboratory. 
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